Endothelial NOS, estrogen receptor β, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer

Journal of Clinical Investigation

Volumn 119, Issue 5, 2009, Pages 1093-1108

  Nanni, Simona ^a,b,c   Benvenuti, Valentina ^a,b   Grasselli, Annalisa ^a,b   Priolo, Carmen ^b,d,e   Aiello, Aurora ^a,c   Mattiussi, Stefania ^f   Colussi, Claudia ^g   Lirangi, Vittoria ^a   Illi, Barbara ^g   D'Eletto, Manuela ^a   Cianciulli, Anna Maria ^a   Gallucci, Michele ^a   De Carli, Piero ^a   Sentinelli, Steno ^a   Mottolese, Marcella ^a   Carlini, Paolo ^a   Strigari, Lidia ^a   Finn, Stephen ^d,e   Mueller, Elke ^d,e   Arcangeli, Giorgio ^a   Gaetano, Carlo ^f   Capogrossi, Maurizio C ^f   Donnorso, Raffaele Perrone ^a   Bacchetti, Silvia ^a   Sacchi, Ada ^a   Pontecorvi, Alfredo ^a,b   Loda, Massimo ^d,e   Farsetti, Antonella ^a,c   more..

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c CNR   (Italy)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^g CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN RECEPTOR BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; NITRIC OXIDE; TUMOR MARKER; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BIOLOGICAL MARKER; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; ENZYME INHIBITOR; ESTRADIOL; GLUCOSE TRANSPORTER 1; HIF1A PROTEIN, HUMAN; NOS3 PROTEIN, HUMAN; SLC2A1 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; EARLY DIAGNOSIS; ESTROGEN THERAPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOXIC CELL; MALE; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRANSCRIPTION INITIATION; TUMOR BIOPSY; CELL HYPOXIA; CELL NUCLEUS; CYTOPLASM; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; PROMOTER REGION; PROSTATE TUMOR; PROTEIN BINDING; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOLOGICAL MARKERS; CELL HYPOXIA; CELL LINE, TUMOR; CELL NUCLEUS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYTOPLASM; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN RECEPTOR BETA; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NITRIC OXIDE SYNTHASE TYPE III; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; RESPONSE ELEMENTS; TELOMERASE; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 66449130218     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35079     Document Type: Article

References (51)

1. Ferlay, J., Bray, F., Pisani, P., and Parkin, D.M. 2004. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. IARC Press. Lyon, France. http://wwwdep. iarc.fr/.
2. Nanni, S., et al. 2006. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol. Cancer Res. 4:79-92.
3. Chi, J.T., et al. 2006. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3:e47.
4. Pouyssegur, J., Dayan, F., and Mazure, N.M. 2006. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 441:437-443.
5. Zhong, H., et al. 1999. Overexpression of hypoxia inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830-5835.
6. Dales, J.P., et al. 2005. Overexpression of hypoxiainducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer. 116:734-739.
7. Gatenby, R.A., and Gillies, R.J. 2004. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer. 4:891-899.
8. Keith, B., and Simon, M.C. 2007. Hypoxia-inducible factors, stem cells, and cancer. Cell. 129:465-472.
9. Ho, S.M., Leung, Y.K., and Chung, I. 2006. Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann. N. Y. Acad. Sci. 1089:177-193.
10. Adams, J.Y., Leav, I., Lau, K.M., Ho, S.M., and Pflueger, S.M. 2002. Expression of estrogen receptor beta in the fetal, neonatal, and prepubertal human prostate. Prostate. 52:69-81.
11. Shapiro, E., et al. 2005. Immunolocalization of estrogen receptor alpha and beta in human fetal prostate. J. Urol. 174:2051-2053.
12. Signoretti, S., and Loda, M. 2001. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am. J. Pathol. 159:13-16.
13. Imamov, O., Shim, G.J., Warner, M., and Gustafsson, J.A. 2005. Estrogen receptor beta in health and disease. Biol. Reprod. 73:866-871.
14. Zhu, X., et al. 2004. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol. 164:2003-2012.
15. Horvath, L.G., et al. 2001. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 61:5331-5335.
16. Leav, I., et al. 2001. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159:79-92.
17. Coulet, F., Nadaud, S., Agrapart, M., and Soubrier, F. 2003. Identification of hypoxia-response element in the human endothelial nitric-oxide synthase gene promoter. J. Biol. Chem. 278:46230-46240.
18. Grasselli, A., et al. 2008. Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ. Res. 103:34-42.
19. Zeng, L., and Xu, Q. 2008. eNOS-ERalpha complex goes to telomerase. Circ. Res. 103:10-12.
20. Chambliss, K.L., and Shaul, P.W. 2002. Estrogen modulation of endothelial nitric oxide synthase. Endocr. Rev. 23:665-686.
21. Brune, B., and Zhou, J. 2007. Nitric oxide and superoxide: interference with hypoxic signaling. Cardiovasc. Res. 75:275-282.
22. Sandau, K.B., Fandrey, J., and Brune, B. 2001. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood. 97:1009-1015.
23. Kasuno, K., et al. 2004. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J. Biol. Chem. 279:2550-2558.
24. Thomas, D.D., et al. 2004. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 101:8894-8899.
25. Lim, K.H., Ancrile, B.B., Kashatus, D.F., and Counter, C.M. 2008. Tumour maintenance is mediated by eNOS. Nature. 452:646-649.
26. Fukumura, D., Kashiwagi, S., and Jain, R.K. 2006. The role of nitric oxide in tumour progression. Nat. Rev. Cancer. 6:521-534.
27. Ying, L., and Hofseth, L.J. 2007. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res. 67:1407-1410.
28. Zhang, W., Kapusta, L.R., Slingerland, J.M., and Klotz, L.H. 1998. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 58:619-621.
29. Sommerfeld, H.J., et al. 1996. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 56:218-222.
30. Semenza, G.L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:721-732.
31. Kyo, S., et al. 1999. Estrogen activates telomerase. Cancer Res. 59:5917-5921.
32. Nishi, H., et al. 2004. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol. Cell. Biol. 24:6076-6083.
33. Carroll, J.S., et al. 2005. Chromosome-wide mapping of estrogen receptor binding reveals longrange regulation requiring the forkhead protein FoxA1. Cell. 122:33-43.
34. Nanni, S., et al. 2002. Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J. Clin. Invest. 110:219-227.
35. Shang, Y., Hu, X., DiRenzo, J., Lazar, M.A., and Brown, M. 2000. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 103:843-852.
36. Jiang, B.H., Semenza, G.L., Bauer, C., and Marti, H.H. 1996. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol. 271:C1172-C1180.
37. Seifeddine, R., et al. 2007. Hypoxia and estrogen co-operate to regulate gene expression in T-47D human breast cancer cells. J. Steroid Biochem. Mol. Biol. 104:169-179.
38. Venkov, C.D., Rankin, A.B., and Vaughan, D.E. 1996. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation. 94:727-733.
39. Klinge, C.M. 1999. Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF). J. Steroid Biochem. Mol. Biol. 71:1-19.
40. Krishnamachary, B., and Semenza, G.L. 2007. Analysis of hypoxia-inducible factor 1alpha expression and its effects on invasion and metastasis. Methods Enzymol. 435:347-354.
41. Kimbro, K.S., and Simons, J.W. 2006. Hypoxiainducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer. 13:739-749.
42. Gordan, J.D., and Simon, M.C. 2007. Hypoxiainducible factors: central regulators of the tumor phenotype. Curr. Opin. Genet. Dev. 17:71-77.
43. Mattiussi, S., et al. 2006. Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: evidence for specialized functions of paxillin. Cardiovasc. Res. 70:578-588.
44. Weihua, Z., et al. 2001. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc. Natl. Acad. Sci. U. S. A. 98:6330-6335.
45. Bossi, G., et al. 2004. Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene. 23:418-425.
46. Signoretti, S., et al. 2002. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 110:633-641.
47. Ogino, S., et al. 2008. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J. Clin. Oncol. 26:5713-5720.
48. [No authors listed]. 1997. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys. 37:1035-1041.
49. Roach, M., 3rd, et al. 2006. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOGASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65:965-974.
50. Kaplan, E.L., and Meier, P. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481.
51. Cox, D.R. 1975. Partial likelihood. Biometrika. 62:269-276.